Brief: Medicenna Presents Preliminary Top-Line Clinical Results From Their Phase 2B Trial Of Mdna55 In Recurrent Glioblastoma
18/06/2019 13:48
June 18 (Reuters) - Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA PRESENTS PRELIMINARY TOP-LINE CLINICAL RESULTS
FROM
THEIR PHASE 2B TRIAL OF MDNA55 IN RECURRENT GLIOBLASTOMA
* MEDICENNA - SAFETY DATA FROM PHASE 2B CLINICAL TRIAL SHOW
SIMILAR SAFETY PROFILE TO PREVIOUS MDNA55 TRIALS
* MEDICENNA THERAPEUTICS CORP - DISEASE CONTROL RATE OF UP
TO 83%
ACHIEVED; EVIDENCE OF IMPROVED SURVIVAL FOR PATIENTS
Source text for Eikon: ID:nCNWGFg40a
Further company coverage: MDNA.TO
((Briefs@thomsonreuters.com;))
Recent news on Medicenna Therapeutics
See all newsBrief: Medicenna Therapeutics - Announces Two New U.S. Patents And One Allowed U.S. Patent Application
Brief: Medicenna Announces The Finalization Of The Terms Of Its Public Offering Of Securities
Brief: Medicenna Announces The Launch Of A Marketed Public Offering Of Securities
Brief: Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim As Chief Medical Officer
Brief: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results